Market Overview

5 Reasons Arrowhead Pharma Is A Hepatitis B Leader

Share:
5 Reasons Arrowhead Pharma Is A Hepatitis B Leader

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) reported positive data in a Phase II study of its lead product ARC-520 for the treatment of hepatitis B surface antigen [HBsAg] in HB envelope antigen-positive [HBeAg+] HBV patients. Chardan Capital’s Madhu Kumar initiated coverage of the company with a Buy rating and price target of $12.

Arrowhead Pharma is focusing on the development and commercialization of RNAi therapies for the treatment of various conditions, including chronic hepatitis B virus infection, alpha-1 antitrypsin deficiency, thrombosis/angioedema, cardiovascular disease, and clear cell renal cell carcinoma.

Kumar outlined several catalysts driving the company’s growth prospects:

  1. In a phase IIa study, ARC-520 achieved >97 percent suppression of HBsAg that was persistent for around four weeks after a single 4 mg/kg dose in combination with daily nucleoside analog (NUC) therapy.
  2. Suppression of HBsAg is likely vital for durable HBV therapy. ARC-520 thus has the potential to generate a robust immune response against HBV.
  3. Nucleoside analog therapies transiently suppress HBV, driving the need for combination therapies like ARC-520 to achieve durable responses.
  4. ARC-520 is more advanced and likely more effective than competing HBV RNAi assets.
  5. Arrowhead Pharma may enter into a partnership soon. Such announcements with RNAi companies are associated with high alpha generation.

Kumar believes Arrowhead Pharma’s ARC-520 may be of interest to larger players like Gilead Sciences, Inc. (NASDAQ: GILD) and Johnson & Johnson (NYSE: JNJ).

Latest Ratings for ARWR

DateFirmActionFromTo
May 2020RBC CapitalInitiates Coverage OnOutperform
May 2020Cantor FitzgeraldReiteratesOverweight
Apr 2020Cantor FitzgeraldUpgradesNeutralOverweight

View More Analyst Ratings for ARWR
View the Latest Analyst Ratings

 

Related Articles (ARWR)

View Comments and Join the Discussion!

Posted-In: Chardan CapitalAnalyst Color Long Ideas Health Care Initiation Analyst Ratings Trading Ideas General Best of Benzinga

Latest Ratings

StockFirmActionPT
TYGB of A SecuritiesUpgrades
ZIONB of A SecuritiesMaintains39.0
RFB of A SecuritiesMaintains13.0
PNCB of A SecuritiesMaintains123.0
HBANB of A SecuritiesMaintains11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com